Business Context and Reporting Period
This Form 8-K Current Report is filed by Nephros, Inc. on November 12, 2013. The filing primarily addresses the entry into a material definitive agreement involving bridge financing and the announcement of a planned rights offering. While the filing references a press release regarding financial results for the third quarter ended September 30, 2013, the specific revenue, profit, and cash flow figures are not contained within the text of this report.
Key Financial Metrics and Capital Structure
The filing details a new debt instrument and a planned equity raise rather than historical operating metrics.
- New Debt: Issued a senior secured note to Lambda Investors LLC with a principal amount of $1.5 million.
- Interest Rate: 12% per annum, increasing to 16% per annum upon default.
- Maturity Date: May 12, 2014.
- Planned Equity Raise: A rights offering of common stock targeting $2.75 million at an expected price of $0.30 per share.
- Transaction Costs: Agreed to pay Lambda Investors an 8% sourcing/transaction fee ($120,000) plus $75,000 for legal fees and expenses.
- Collateral: The note is secured by a first priority lien on all company property, including intellectual property.
Material Changes and Covenants
The company has entered into restrictive covenants that limit its operational flexibility while the note is outstanding. These restrictions include prohibitions on:
- Merging with another company.
- Selling a material amount of assets.
- Incurring additional indebtedness.
- Repaying existing indebtedness (except as specified).
- Declaring or paying dividends in cash, property, or securities.
Additionally, the company agreed to amend the expiration date of existing warrants held by Lambda Investors from March 10, 2017, to the five-year anniversary of the closing of the rights offering. The rights offering price of $0.30 per share triggers full ratchet anti-dilution protection for certain warrants with a $0.40 exercise price.
Outlook, Risks, and Contingencies
Management has issued significant forward-looking statements highlighting severe risks to the company's viability and operations:
- Going Concern: Explicit risk that the company may not be able to continue as a going concern.
- Product Recalls: Voluntary recalls of point of use (POU) and DSU in-line ultrafilters used in hospital water treatment could lead to claims, proceedings, and adverse impacts on sales.
- Liability and Safety: Risks of product-related deaths, serious injuries, or malfunctions triggering class action lawsuits and regulatory enforcement.
- Funding: Uncertainty regarding the ability to obtain necessary funding on favorable terms to continue operations.
- Regulatory: Potential enforcement actions by the FDA if products or marketing materials violate the FDC Act or other regulations.
Investor Verification Checklist
- Verify the effectiveness of the Form S-1 registration statement required for the $2.75 million rights offering.
- Confirm the status of the voluntary product recalls and any associated legal proceedings or financial liabilities.
- Review the full text of the Senior Secured Note (Exhibit 10.1) to understand specific default triggers and prepayment conditions.
- Assess the company's current cash runway given the "going concern" risk disclosure and the reliance on the rights offering proceeds to prepay the new note.
- Check for any updates on the exercise of the basic subscription privilege by Lambda Investors in the rights offering.